A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Aziz Ansari, an award-winning actor, director, writer and comedian, brings his “Hypothetical Tour” to the Gallo Center. He co ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, ...